This discovery also points to a potential new therapeutic approach, as SGLT2 inhibitors, already FDA-approved for treating type 2 diabetes, could be repurposed for treating high-grade astrocytomas. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.